On 15 January 2015, orphan designation (EU/3/14/1409) was granted by the European Commission to Designerx Europe Limited, United Kingdom, for pegylated recombinant arginine deiminase for the treatment of malignant mesothelioma.
The sponsorship was transferred to Polaris Pharmaceuticals Ireland Limited, Ireland, in March 2019.
Pegylated recombinant arginine deiminase (pegargiminase)
Treatment of malignant mesothelioma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: